Targets › TLR8
12 programs from 11 companies in 18 trials: 8 Phase 2, 8 Phase 1, 2 Phase 3; Oncology, Immunology, Infectious disease; next expected readout Dec 2026.
Endosomal receptor that plays a key role in innate and adaptive immunity. Controls host immune response against pathogens through recognition of RNA degradation products specific to microorganisms that are initially processed by RNASET2. (UniProt, Q9NR97)
Open in Phaseline: the race on TLR8, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Merck KGaA | Enpatoran Toll-like receptor 8 antagonist; Toll-like receptor 7 antagonist | TLR8, TLR7 | Phase 3 | Systemic Lupus Erythematosus (SLE); Systematic Lupus Erythematosus | May 2029 |
| Eikon Therapeutics | EIK1001 Toll-like receptor 7/8 (TLR 7/8) agonist | TLR7, TLR8 | Phase 2 | NSCLC; Advanced Melanoma; Non Small Cell Lung Cancer (Squamous or Non Squamous) | Dec 2026 |
| M.D. Anderson Cancer Center | SAR445877 TLR7/8 agonist | TLR7, TLR8 | Phase 2 | Non-Small Cell Lung Cancer; Phase 1 | Feb 2028 |
| Merck KGaA | Enpatoran (M5049) Toll-like receptor 8 antagonist; Toll-like receptor 7 antagonist | TLR8, TLR7 | Phase 2 | Systemic Lupus Erythematosus | Aug 2028 |
| Beeline Medicines | Afimetoran (BLN-256) Toll-like receptor 8 inhibitor; Toll-like receptor 7 inhibitor | TLR8, TLR7 | Phase 2 | Systemic Lupus Erythematosus; Cutaneous Lupus Erythematosus (CLE) | Apr 2029 |
| Solstice Oncology | Porustobart Toll-like receptor 8 (TLR8) agonist | TLR8 | Phase 2 | Colon Cancer | Sep 2029 |
| National Institute of Allergy and Infectious Diseases (NIAID) | 3M-052-AF Toll-like receptor 7/8 agonist | TLR7, TLR8 | Phase 1 | Hiv; HIV | Dec 2026 |
| Bolt Biotherapeutics | BDC-4182 Anti-CLDN18.2 monoclonal antibody conjugated to TLR7/8 dual agonist | CLDN18, TLR7, TLR8 | Phase 1 | Gastric Cancer Adenocarcinoma Metastatic | May 2027 |
| Ascendis Pharma Oncology Division | TransCon TLR7/8 Agonist TLR7/8 agonist with extended half-life via TransCon technology | TLR7, TLR8 | Phase 1 | Advanced Solid Tumor | Aug 2027 |
| HighField Biopharmaceuticals | HF50 Liposome-encapsulated bifunctional therapeutic; HER2-redirected T-cell engager with TLR7/8 | ERBB2, TLR7, TLR8 | Phase 1 | Advanced Solid Tumors | Jun 2028 |
| United Immunity | UI-102 TLR7/8 agonist encapsulated in Cholesteryl Pullulan Nanoparticle | TLR7, TLR8 | Phase 1 | Advanced Cancer | Mar 2030 |
| Inimmune | INI-4001 TLR7/8 agonist | TLR7, TLR8 | Phase 1 | Advanced Solid Tumor | – |
Systemic Lupus Erythematosus (2) Advanced Solid Tumor (2) Systemic Lupus Erythematosus (SLE) (1) Systematic Lupus Erythematosus (1) NSCLC (1) Advanced Melanoma (1) Non Small Cell Lung Cancer (Squamous or Non Squamous) (1) Advanced Cancer (1) Cutaneous Lupus Erythematosus (CLE) (1) Hiv (1) HIV (1) Non-Small Cell Lung Cancer (1)
small molecule (6), mixed (5), antibody (1)
Merck KGaA (2) Eikon Therapeutics (1) United Immunity (1) Beeline Medicines (1) National Institute of Allergy and Infectious Diseases (NIAID) (1) M.D. Anderson Cancer Center (1) Solstice Oncology (1) HighField Biopharmaceuticals (1) Ascendis Pharma Oncology Division (1) Bolt Biotherapeutics (1) Inimmune (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.